Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Public policy

1505MO - Improving cancer care through broader access to quality biomarker testing: An IQN Path, ECPC and EFPIA initiative

Date

18 Sep 2021

Session

Mini oral session - Public policy

Presenters

Nicola Normanno

Citation

Annals of Oncology (2021) 32 (suppl_5): S1102-S1110. 10.1016/annonc/annonc711

Authors

N. Normanno1, K. Apostolidis2, M. Akkermans3, R. Al Dieri4, C. Bedard Pfeiffer5, I. Cattaneo6, Z.C. Deans7, J. Emch8, J.A. Fairley7, P. Fivey9, S. Hall10, J. Maas11, A. Martinez12, H. Moch13, S. Nielsen14, T. Pilz15, E. Rouleau16, P.J. Simon17, M. van Meerveld18, N. Wolstenholme19

Author affiliations

  • 1 President, IQN Path ASBL and Istituto Nazionale Tumori "Fondazione G. Pascale" - IRCCS, 80131 - Naples/IT
  • 2 Board Member, European Cancer Patient Coalition (ECPC), 1000 - Brussels/BE
  • 3 Global Director Of Market Access, Oncology, MSD, Zurich/CH
  • 4 Director General, European Society of Pathology (ESP), 1070 - Brussels/BE
  • 5 Global Access Leader, Personalised Healthcare, Roche Pharmaceuticals, 4000 - Basel/CH
  • 6 Executive Director Oncology Policy & Healthcare Systems, Novartis Oncology, 21040 - Origgio/IT
  • 7 Laboratory Medicine, GenQA, EH16 4UX - Edinburgh/GB
  • 8 Vice President, Diagnostics Strategy, GSK, Collegeville/US
  • 9 Senior Precision Medicine Policy Lead, AstraZeneca, Royston/GB
  • 10 Marketing Director Companion Diagnostics, Novartis Pharmaceuticals, East Horsley/GB
  • 11 Secretary General, Deutsche Gesellschaft für Pathologie e.V. (DGP), Berlin/DE
  • 12 Director Eqas Gcp, Sociedad Espanola de Anatomia Patologica (SEAP), Madrid/ES
  • 13 President, European Society of Pathology (ESP), 1070 - Brussels/BE
  • 14 Director, NordiQC, Aalborg/DK
  • 15 Director, QuIP GmbH, 10115 - Berlin/DE
  • 16 Director, Gen&Tiss, 94805 - Villejuif/FR
  • 17 Managing Director, EMQN, Manchester/GB
  • 18 Director Oncology Policy Eucan, MSD, Kriens/CH
  • 19 Deputy Director, EMQN, Manchester/GB
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1505MO

Background

Predictive biomarkers are essential for selecting the best therapeutic strategy in cancer patients. Yet, the promise of superior treatment outcomes cannot be realised if patients do not have access to high quality biomarker testing. The International Quality Network for Pathology (IQN Path ASBL), the European Cancer Patient Coalition (ECPC) and the European Federation of Pharmaceuticals Industries and Associations (EFPIA) launched an initiative to evaluate the access to and quality of biomarker testing (BMT) across Europe.

Methods

Four access metrics (laboratory access, test availability, test reimbursement, test order rate) and three quality metrics (quality scheme participation, laboratory accreditation, test turnaround time) were applied. Secondary sources included surveys of 141 laboratory managers and of 1.665 patients, and 58 in-depth interviews with laboratory managers, physicians, and payers. The findings were reviewed over a series of meetings by IQN Path, ECPC, EFPIA and key opinion leaders, in order to develop an unbiased view of existing test access barriers and to establish a consensus on critical policy recommendations for immediate, concerted action.

Results

A detailed mapping showed the status of each country according to the applied metrics and six key barriers to BMT were identified in the majority of European countries: 1) Limited availability of precision medicine linked to biomarkers; 2) Unclear value assessment approaches for diagnostic tests; 3) Very diverse laboratory infrastructure, capabilities and referral pathways; 4) Limited availability of public funding to support biomarker testing; 5) Limited stakeholder awareness and education; 6) Inconsistent participation of laboratories in quality assurance schemes.

Conclusions

To address the barriers to high quality BMT, multi-disciplinary and concerted action is needed. Short-term and long-term policy recommendations to address the shortcomings in BMT access would be presented and discussed with the ESMO audience. The project was initiated and financed by IQN Path, ECPC and EFPIA together with a consortium of industry and academic partners, and conducted by L.E.K. Consulting.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

EFPIA and IQN Path.

Funding

EFPIA and IQN Path.

Disclosure

N. Normanno: Financial Interests, Personal, Other, Speaker's fee and/or advisory board: MSD; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Qiagen; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Bayer; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Biocartis; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Illumina; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Incyte; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Roche; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: BMS; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Merck; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Thermo Fisher; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: AstraZeneca; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Sanofi; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Eli Lilly; Financial Interests, Personal, Other, Speaker's fee and/or advisory board: Novartis; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Research Grant: Thermo Fisher; Financial Interests, Institutional, Research Grant: Qiagen; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Biocartis; Financial Interests, Institutional, Research Grant: Illumina; Financial Interests, Institutional, Research Grant: Blueprint; Non-Financial Interests, Personal, Member of the Board of Directors: International Quality Network for Pathology (IQN Path); Non-Financial Interests, Personal, Member of the Board of Directors: Italian Cancer Society (SIC). M. Akkermans: Financial Interests, Personal, Full or part-time Employment: MSD. C. Bedard Pfeiffer: Financial Interests, Personal, Full or part-time Employment: Roche. I. Cattaneo: Financial Interests, Personal, Full or part-time Employment: Novartis. J. Emch: Financial Interests, Personal, Full or part-time Employment: GSK. P. Fivey: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. S. Hall: Financial Interests, Personal, Full or part-time Employment: Novartis. E. Rouleau: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: Clovis; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Other, Travel: BMS; Financial Interests, Personal, Other, Travel: AstraZeneca. M. van Meerveld: Financial Interests, Personal, Full or part-time Employment: MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.